We are live on ! Find out more
LPC

Lion Point Capital Portfolio holdings

AUM $16.7M
1-Year Est. Return 119.35%
This Fund
S&P 500
This Quarter Est. Return
-4.4%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$224M
AUM Growth
+$3.13M
Cap. Flow
+$13.8M
Cap. Flow %
6.13%
Top 10 Hldgs %
93.45%
Holding
37
New
6
Increased
4
Reduced
4
Closed
6

Top Buys

1
TVTX icon
Travere Therapeutics
TVTX
+$1.1M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$1.07M
3
HUMA icon
Humacyte
HUMA
+$778K
4
REPL icon
Replimune Group
REPL
+$687K
5
INSM icon
Insmed
INSM
+$457K

Top Sells

1
CHRD icon
Chord Energy
CHRD
+$15.7M
2
ARDX icon
Ardelyx
ARDX
+$1.37M
3
TSVT
2seventy bio
TSVT
+$1.13M
4
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$933K
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$761K

Sector Composition

1 Technology 28.16%
2 Healthcare 10.07%
3 Consumer Discretionary 1.42%
4 Energy 1.05%
5 Communication Services 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SMTC icon
1
CALL
Semtech
SMTC
$11.9B
$64.4M 28.68%
2,500,000
– –
SMTC icon
2
Semtech
SMTC
$11.9B
$63.2M 28.14%
2,452,855
– –
IWM icon
3
PUT
iShares Russell 2000 ETF
IWM
$82.6B
$29.2M 12.99%
+165,000
New +$31M
SPY icon
4
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$782B
$21.4M 9.52%
50,000
– –
MRNS
5
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$17.3M 7.7%
2,145,337
-112,184
-5% -$933K
ARDX icon
6
Ardelyx
ARDX
$1.27B
$4.8M 2.14%
1,176,667
-350,000
-23% -$1.37M
BFI
7
DELISTED
BurgerFi International, Inc. Common Stock
BFI
$3.19M 1.42%
2,745,938
– –
BATL icon
8
Battalion Oil
BATL
$34.6M
$2.35M 1.05%
380,891
– –
KNSA icon
9
Kiniksa Pharmaceuticals
KNSA
$4.7B
$2.27M 1.01%
130,691
– –
INSM icon
10
Insmed
INSM
$23.3B
$1.78M 0.79%
70,335
+20,000
+40% +$457K
MCRB icon
11
Seres Therapeutics
MCRB
$50.2M
$1.65M 0.73%
34,590
– –
BLUE
12
DELISTED
bluebird bio
BLUE
$1.62M 0.72%
26,563
– –
MIST icon
13
Milestone Pharmaceuticals
MIST
$154M
$1.4M 0.62%
450,207
– –
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
$1.23M 0.55%
82,425
-17,000
-17% -$225K
DRRX
15
DELISTED
DURECT Corp
DRRX
$1.06M 0.47%
427,455
-174,209
-29% -$594K
MIRM icon
16
Mirum Pharmaceuticals
MIRM
$7.16B
$853K 0.38%
27,000
– –
FENC icon
17
Fennec Pharmaceuticals
FENC
$363M
$826K 0.37%
110,000
– –
AVDL
18
DELISTED
Avadel Pharmaceuticals
AVDL
$824K 0.37%
+80,000
New +$1.07M
ACRS icon
19
Aclaris Therapeutics
ACRS
$749M
$794K 0.35%
115,898
+6,000
+5% +$51.3K
TVTX icon
20
Travere Therapeutics
TVTX
$5.14B
$697K 0.31%
+78,000
New +$1.1M
HUMA icon
21
Humacyte
HUMA
$178M
$689K 0.31%
+235,000
New +$778K
REPL icon
22
Replimune Group
REPL
$799M
$599K 0.27%
+35,000
New +$687K
SNDX icon
23
Syndax Pharmaceuticals
SNDX
$2.01B
$501K 0.22%
34,500
– –
WHWK
24
Whitehawk Therapeutics
WHWK
$192M
$399K 0.18%
82,423
– –
HARP
25
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$332K 0.15%
82,458
+36,807
+81% +$273K
1
2

Similar funds

PA
PPM America Chicago, Illinois $16.6M AUM 31.99% 1-Year Est. Return
PA
Prossimo Advisors San Luis Obispo, California $16.4M AUM 14% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
SRA
Summit Rock Advisors New York $16M AUM
CP
Covalent Partners Concord, Massachusetts $17.6M AUM 2.91% 1-Year Est. Return
B
BP London, United Kingdom $17.7M AUM 12.34% 1-Year Est. Return
CVV
Curative Ventures V Dallas, Texas $15.6M AUM 52.53% 1-Year Est. Return

Lion Point Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Lion Point Capital held 37 positions worth $224M, up 1.4% from $221M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Lion Point Capital deployed $13.8M of net new capital in Q3 2023, opening 6 new positions and adding to 4 existing holdings. Its largest new stake was Travere Therapeutics: 78,000 shares worth $697K.

By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 28% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Ardelyx, an estimated $1.37M trimmed.

  • Lion Point Capital's largest Q3 2023 buy was Travere Therapeutics: 78,000 shares worth $697K.
  • Lion Point Capital added most to Insmed in Q3 2023, an estimated $457K increase.
  • Lion Point Capital's biggest Q3 2023 reduction was Ardelyx, cutting an estimated $1.37M.
  • Lion Point Capital fully exited Chord Energy in Q3 2023, selling an estimated $15.7M.
  • Lion Point Capital's ten largest holdings make up 93% of its $224M portfolio in Q3 2023.
  • Lion Point Capital opened 6 new positions and closed 6 in Q3 2023.
  • Lion Point Capital's portfolio value rose 1.4% quarter-over-quarter to $224M.

Based on Lion Point Capital's 13F filing for Q3 2023, filed 14 Nov 2023.